Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PDS Biotechnology (PDSB), Cardiol Therapeutics (CRDL...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Cardiol Therapeutics ( ($TSE:CRDL) ) just unveiled an update. Cardiol Therapeutics filed a Form 6-K on August 12, 2026, reporting unaudited condens...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRDL	$2.20	+1.85%	1.07M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRDL	$2.20	+1.9%	1.07M
3
4
5
6

CRDL

Get Cardiol Therapeutics Inc. Data in Excel

Get Cardiol Therapeutics Inc. Data in Excel